Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
1.
Regul Toxicol Pharmacol ; 120: 104840, 2021 Mar.
Article in English | MEDLINE | ID: mdl-33321148

ABSTRACT

In 2017, JECFA requested reproductive and developmental toxicity studies to finalize an acceptable daily intake for solvent rosemary extracts. Thus, an OECD 421 reproductive/developmental toxicity study was conducted using an acetone rosemary extract that complied with JECFA and EFSA food additive specifications. Rosemary extract was provided to rats at dietary concentrations of 0 (control), 2100, 3600, or 5000 mg/kg, for 14 days before mating, during mating, and thereafter (throughout gestation and up to Lactation Day 13 for females) until necropsy. General toxicity (clinical signs, body weight, food consumption) and reproductive/developmental outcomes (fertility and mating performance, estrous cycles, anogenital distance, thyroid hormones, reproductive organ weights, thyroid histopathology) were assessed. There were no signs of general toxicity and no effects on reproduction; thus, the highest concentration tested (equivalent to mean daily intakes of 316 or 401 mg/kg bw/day [149 or 189 mg/kg bw/day carnosol and carnosic acid] for males and females, respectively) was established as the no-observed-adverse-effect level for general and reproductive toxicity. Dose-related reductions in T4 were observed for Day 13 pups (not seen on Day 4) but were not accompanied by thyroid weight changes or histopathological findings; further investigations are required to determine the biological relevance of these T4 reductions.


Subject(s)
Acetone/toxicity , Genitalia/drug effects , Plant Extracts/toxicity , Reproduction/drug effects , Rosmarinus , Animals , Animals, Newborn , Developmental Disabilities/chemically induced , Developmental Disabilities/pathology , Drug Evaluation, Preclinical/methods , Female , Genitalia/physiology , Male , No-Observed-Adverse-Effect Level , Organ Size , Plant Extracts/isolation & purification , Pregnancy , Rats , Reproduction/physiology
2.
Food Sci Nutr ; 8(1): 456-478, 2020 Jan.
Article in English | MEDLINE | ID: mdl-31993171

ABSTRACT

Arabinase is an enzyme recognized for its ability to degrade arabinan, a plant cell wall constituent. It has been applied in the food industry most commonly for juice processing. One commercial source of arabinase is Aspergillus tubingensis (A. tubingensis), a black Aspergillus species. Given the intended use in food for human consumption, and noting its potential presence at trace levels in finished products, a series of safety studies including in vitro Ames and chromosome aberration assays, in vivo mammalian erythrocyte micronucleus and alkaline comet assays, and a 90-day rat oral toxicity study were conducted. No test article-related mutagenic activity was observed in the Ames assay. Although positive activity was observed in the chromosome aberration assay, this was not replicated in the in vivo genotoxicity assays including in preabsorptive cells. In the subchronic toxicity study, no test article-related adverse effects were observed following oral administration of arabinase at doses of 15.3, 153, or 1,530 mg total organic solids (TOS)/kg body weight/day to Sprague Dawley rats. The no-observed-adverse-effect level was considered to be the highest dose tested (1,530 mg TOS/kg body weight/day). The results of the genotoxicity studies and the subchronic toxicity study support the safe use of arabinase from A. tubingensis in food production.

3.
Int J Mol Sci ; 19(7)2018 Jul 17.
Article in English | MEDLINE | ID: mdl-30018258

ABSTRACT

High-grade serous ovarian carcinoma (HGSOC) is the most frequent histological type of ovarian cancer and the one with worst prognosis. Unfortunately, the majority of established ovarian cancer cell lines which are used in the research have unclear histological origin and probably do not represent HGSOC. Thus, new and reliable models of HGSOC are needed. Ascitic fluid from a patient with recurrent HGSOC was used to establish a stable cancer cell line. Cells were characterized by cytogenetic karyotyping and short tandem repeat (STR) profiling. New generation sequencing was applied to test for hot-spot mutations in 50 cancer-associated genes and fluorescence in situ hybridization (FISH) analysis was used to check for TP53 status. Cells were analyzed for expression of several marker genes/proteins by reverse-transcription polymerase chain reaction (RT-PCR), fluorescence-activated cell sorting (FACS), and immunocytochemistry (ICC). Functional tests were performed to compare OVPA8 cells with five commercially available and frequently used ovarian cancer cell lines: SKOV3, A2780, OVCAR3, ES2, and OAW42. Our newly-established OVPA8 cell line shows morphologic and genetic features consistent with HGSOC, such as epithelial morphology, multiple chromosomal aberrations, TP53 mutation, BRCA1 mutation, and loss of one copy of BRCA2. The OVPA8 line has a stable STR profile. Cells are positive for EpCAM, CK19, and CD44; they have relatively low plating efficiency/ability to form spheroids, a low migration rate, and intermediate invasiveness in matrigel, as compared to other ovarian cancer lines. OVPA8 is sensitive to paclitaxel and resistant to cisplatin. We also tested two FGFR inhibitors; OVPA8 cells were resistant to AZD4547 (AstraZeneca, London, UK), but sensitive to the new inhibitor CPL304-110-01 (Celon Pharma, Lomianki/Kielpin, Poland). We have established and characterized a novel cell line, OVPA8, which can be a valuable preclinical model for studies on high-grade serous ovarian cancer.


Subject(s)
Cystadenocarcinoma, Serous/pathology , Ovarian Neoplasms/pathology , BRCA1 Protein , BRCA2 Protein , Cell Line, Tumor , Chromosome Aberrations , Cystadenocarcinoma, Serous/genetics , Cystadenocarcinoma, Serous/metabolism , Female , Genetic Predisposition to Disease/genetics , High-Throughput Nucleotide Sequencing/methods , Humans , Karyotyping , Mutation , Neoplasm Grading , Ovarian Neoplasms/genetics , Ovarian Neoplasms/metabolism , Tandem Repeat Sequences/genetics , Tumor Suppressor Protein p53/genetics , Tumor Suppressor Protein p53/metabolism
5.
Sci Rep ; 7: 42074, 2017 02 09.
Article in English | MEDLINE | ID: mdl-28181547

ABSTRACT

Medullary thyroid cancer (MTC) can be caused by germline mutations of the RET proto-oncogene or occurs as a sporadic form. It is well known that RET mutations affecting the cysteine-rich region of the protein (MEN2A-like mutations) are correlated with different phenotypes than those in the kinase domain (MEN2B-like mutations). Our aim was to analyse the whole-gene expression profile of MTC with regard to the type of RET gene mutation and the cancer genetic background (hereditary vs sporadic). We studied 86 MTC samples. We demonstrated that there were no distinct differences in the gene expression profiles of hereditary and sporadic MTCs. This suggests a homogeneous nature of MTC. We also noticed that the site of the RET gene mutation slightly influenced the gene expression profile of MTC. We found a significant association between the localization of RET mutations and the expression of three genes: NNAT (suggested to be a tumour suppressor gene), CDC14B (involved in cell cycle control) and NTRK3 (tyrosine receptor kinase that undergoes rearrangement in papillary thyroid cancer). This study suggests that these genes are significantly deregulated in tumours with MEN2A-like and MEN2B-like mutations; however, further investigations are necessary to demonstrate any clinical impact of these findings.


Subject(s)
Carcinoma, Neuroendocrine/genetics , Discoidin Domain Receptor 2/analysis , Dual-Specificity Phosphatases/analysis , Gene Expression Profiling , Membrane Proteins/analysis , Mutation , Nerve Tissue Proteins/analysis , Proto-Oncogene Proteins c-ret/genetics , Thyroid Neoplasms/genetics , Adult , Aged , Carcinoma, Neuroendocrine/pathology , Discoidin Domain Receptor 2/genetics , Dual-Specificity Phosphatases/genetics , Female , Humans , Male , Membrane Proteins/genetics , Middle Aged , Nerve Tissue Proteins/genetics , Proto-Oncogene Mas , Thyroid Neoplasms/pathology
6.
Pol J Pathol ; 66(4): 376-82, 2015 Dec.
Article in English | MEDLINE | ID: mdl-27003769

ABSTRACT

We analyzed the prognostic significance of indoleamine-2,3-dioxygenase (IDO) and type 1 receptors for transforming growth factor beta (TGF-ßR1) and interferon gamma (IFN-γR1) in resected nodal metastases of 48 malignant melanoma patients. In 32 cases the corresponding skin tumors were available. We used immunohistochemical (IHC) staining which was assessed by pathologists and by a computer-aided algorithm that yielded quantitative results, both absolute and relative. We correlated the results with the patient outcome. We identified absolute computer-assessed IDO levels as positively correlated with increased risk of death in a multivariate model (HR = 1.02; 95% CI: 1.002-1.04; p = 0.03). In univariate analysis, patients with IDO levels below the median had a better overall survival time (30.3 vs. 17.5 months; p = 0.03). TGF-ßR1 and IFN-γR1 expression was modestly correlated (R = 0.34; p lt; 0.05) and TGF-ßR1 expression was lower in lymph nodes than in matched primary skin tumors (Z = 2.87; p = 0.004). The pathologists' and computer-aided IHC assessment demonstrated high correlation levels (R = 0.61, R = 0.74 and R = 0.88 for IDO, TGF-ßR1 and IFN-γR1, respectively). Indoleamine-2,3-dioxygenase is prognostic for the patient outcome in melanoma with nodal involvement and should be investigated prospectively for its predictive significance. IHC assessment by computer-aided methods is recommended as its gives IHC more objectivity and reproducibility. ecting mismatch repair deficiency. Association of CDX2 and PMS2 in the present study is necessary to conduct further genetic and pathological studies focusing on these two markers together.


Subject(s)
Indoleamine-Pyrrole 2,3,-Dioxygenase/metabolism , Lymph Nodes/enzymology , Melanoma/enzymology , Receptors, Interferon/metabolism , Receptors, Transforming Growth Factor beta/metabolism , Skin Neoplasms/enzymology , Adult , Aged , Aged, 80 and over , Female , Humans , Lymph Nodes/pathology , Lymphatic Metastasis , Male , Melanoma/pathology , Middle Aged , Prognosis , Skin Neoplasms/pathology , Young Adult , Interferon gamma Receptor
7.
Ann Transplant ; 17(2): 53-61, 2012.
Article in English | MEDLINE | ID: mdl-22743723

ABSTRACT

BACKGROUND: Non-enzymatic coupling of protein and lipid cellular structures with glucose leading to the formation of advanced glycation end products (AGE) plays a role in aging and the development of diabetic complications, but its contribution to myocardial pathology is unclear. We aimed to assess the role of heart failure on AGE formation in patients with or without diabetes mellitus type 2 (DM2). MATERIAL/METHODS: Heart tissue specimens from 136 patients undergoing transplantation were grouped as follows: 14 cases of ischemic cardiomyopathy (ICM) and DM2, 8 cases of dilated cardiomyopathy (DCM) and DM2, 67 cases of ICM without DM2, and 47 cases of DCM without DM2. Fourteen heart samples were from the autopsies of patients with DM2 without heart disease, and 20 heart samples were from organ donors in whom the heart was wasted. AGE deposits were localized immunohistochemically counted using a semiquantitative scale and characterized by their staining pattern. RESULTS: Positive staining was present in all samples from both cardiomyopathy groups with DM2, in 71% of healthy hearts from the DM2 subjects, in 51% of ICM non-diabetic hearts, and in 38% of DCM non-diabetic hearts, and in only 15% of the organ donors. Mixed-diffuse and granular AGE patterns were characteristic for DM2, while a diffuse pattern was more frequently observed in heart failure patients without diabetes. The semiquantitative results supported increased AGE accumulation in patients with DM2 and/or cardiomyopathy. CONCLUSIONS: The amount of AGE in cardiomyocytes increases significantly in both diabetes and heart failure, with a staining pattern typical for each condition.


Subject(s)
Diabetes Mellitus, Type 2/metabolism , Glycation End Products, Advanced/metabolism , Heart Failure/metabolism , Myocardium/metabolism , Myocytes, Cardiac/metabolism , Adult , Aged , Cardiomyopathy, Dilated/complications , Cardiomyopathy, Dilated/metabolism , Cardiomyopathy, Dilated/pathology , Cardiomyopathy, Dilated/surgery , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/surgery , Female , Heart Failure/complications , Heart Failure/pathology , Heart Failure/surgery , Heart Transplantation , Humans , Male , Middle Aged , Myocardial Ischemia/complications , Myocardial Ischemia/metabolism , Myocardial Ischemia/pathology , Myocardial Ischemia/surgery , Myocardium/pathology , Myocytes, Cardiac/pathology
8.
J Heart Lung Transplant ; 30(5): 558-64, 2011 May.
Article in English | MEDLINE | ID: mdl-21212000

ABSTRACT

BACKGROUND: Disturbed glucose metabolism, particularly in diabetes, is an important but not the sole factor leading to advanced glycation end-product (AGE) formation. The AGE amount and its distribution in cardiopathic myocardial tissues in the presence or absence of diabetes are not well documented. The aim of this study was to assess AGE deposition in unaffected myocardial vessels in heart failure patients with and without diabetes mellitus type 2 (DM2) undergoing transplantation. METHODS: The following groups were established: 14 hearts harvested from subjects with ischemic cardiopathy and DM2; 8 hearts from subjects with dilated cardiopathy with DM2; 67 hearts from subjects with ischemic cardiopathy; 47 hearts from subjects with dilated cardiopathy; and 14 hearts from autopsy cases with diagnosed DM2. A control group consisted of 20 heart donors. AGE localization was determined immunohistochemically in tissue sections. A semi-quantitative scale was used to assess reaction intensity in arteries, arterioles, capillaries, venules and veins. RESULTS: Both types of cardiomyopathy increased AGE accumulation in intramyocardial veins more than in arteries. The presence of DM2 significantly increased AGE in arterioles and capillaries, especially when coexisting with cardiomyopathy. The type of cardiopathy did not influence the pattern of AGE accumulation in myocardial vessels. CONCLUSION: Both chronic heart failure and DM2 intensified AGE pathology and changed the susceptibility of myocardial vasculature to glycation. However, chronic heart failure increases AGE deposition mostly in veins, whereas DM2 predisposes arterioles to AGE accumulation.


Subject(s)
Coronary Vessels/metabolism , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/metabolism , Glycation End Products, Advanced/metabolism , Heart Failure/complications , Heart Failure/metabolism , Adult , Autopsy , Capillaries/metabolism , Case-Control Studies , Chronic Disease , Female , Heart Failure/surgery , Heart Transplantation , Humans , Male , Middle Aged , Veins/metabolism
9.
Int J Radiat Oncol Biol Phys ; 77(2): 438-46, 2010 Jun 01.
Article in English | MEDLINE | ID: mdl-19733016

ABSTRACT

PURPOSE: To determine the prognostic and predictive values of molecular marker expression profiles based on data from a randomized clinical trial of postoperative conventional fractionation (p-CF) therapy versus 7-day-per-week postoperative continuous accelerated irradiation (p-CAIR) therapy for squamous cell cancer of the head and neck. METHODS AND MATERIALS: Tumor samples from 148 patients (72 p-CF and 76 p-CAIR patients) were available for molecular studies. Immunohistochemistry was used to assess levels of EGFR, nm23, Ki-67, p-53, and cyclin D1 expression. To evaluate the effect of fractionation relative to the expression profiles, data for locoregional tumor control (LRC) were analyzed using the Cox proportional hazard regression model. Survival curves were compared using the Cox f test. RESULTS: Patients who had tumors with low Ki-67, low p-53, and high EGFR expression levels and oral cavity/oropharyngeal primary cancer sites tended to benefit from p-CAIR. A joint score for the gain in LRC from p-CAIR based of these features was used to separate the patients into two groups: those who benefited significantly from p-CAIR with respect to LRC (n = 49 patients; 5-year LRC of 28% vs. 68%; p = 0.01) and those who did not benefit from p-CAIR (n = 99 patients; 5-year LRC of 72% vs. 66%; p = 0.38). The nm23 expression level appeared useful as a prognostic factor but not as a predictor of fractionation effect. CONCLUSIONS: These results support the studies that demonstrate the potential of molecular profiles to predict the benefit from accelerated radiotherapy. The molecular profile that favored accelerated treatment (low Ki-67, low p-53, and high EGFR expression) was in a good accordance with results provided by other investigators. Combining individual predictors in a joint score may improve their predictive potential.


Subject(s)
Biomarkers, Tumor/analysis , Carcinoma, Squamous Cell/chemistry , Carcinoma, Squamous Cell/radiotherapy , Head and Neck Neoplasms/chemistry , Head and Neck Neoplasms/radiotherapy , Adult , Aged , Carcinoma, Squamous Cell/mortality , Carcinoma, Squamous Cell/secondary , Cyclin D1/analysis , ErbB Receptors/analysis , Female , Head and Neck Neoplasms/mortality , Humans , Ki-67 Antigen/analysis , Laryngeal Neoplasms/chemistry , Laryngeal Neoplasms/radiotherapy , Male , Middle Aged , Mouth Neoplasms/chemistry , Mouth Neoplasms/radiotherapy , NM23 Nucleoside Diphosphate Kinases/analysis , Neoplasm Recurrence, Local/mortality , Oropharyngeal Neoplasms/chemistry , Oropharyngeal Neoplasms/radiotherapy , Proportional Hazards Models , Radiotherapy/methods , Radiotherapy Dosage , Risk Factors , Tumor Suppressor Protein p53/analysis
10.
Int J Toxicol ; 28(5): 341-56, 2009.
Article in English | MEDLINE | ID: mdl-19815842

ABSTRACT

The peptide product, Valtyron, is obtained via enzymatic hydrolysis of sardine muscle. Although the safety and efficacy of the sardine peptide product have been evaluated in human studies, sardine peptides have not been identified as the subject of toxicological testing. In this study, the sardine peptide product did not exhibit any mutagenic activity in Salmonella typhimurium or Escherichia coli WP2uvrA. Likewise, the sardine peptide product was not associated with clastogenic properties in mouse bone marrow cells in a micronucleus assay. An oral rat LD(50) value of greater than 10,000 mg per kilogram of body weight was determined for peptide alpha-1000, and in rats administered peptide alpha-1000 by gavage at levels up to 5000 mg per kilogram of body weight per day for 28 days, no compound-related differences were observed in standard toxicological parameters. The results of these studies support the safety of the sardine peptide product for use in food for human consumption as a dietary source of peptides available from sardines.


Subject(s)
Fishes , Muscle Proteins/toxicity , Oligopeptides/toxicity , Peptide Fragments/toxicity , Administration, Oral , Animals , Bone Marrow/drug effects , Dose-Response Relationship, Drug , Escherichia coli/drug effects , Escherichia coli/genetics , Female , Fishes/metabolism , Hydrolysis , Lethal Dose 50 , Male , Mice , Mice, Inbred ICR , Micronuclei, Chromosome-Defective/chemically induced , Muscle Proteins/chemistry , Muscle Proteins/isolation & purification , Mutagenicity Tests , Oligopeptides/chemistry , Oligopeptides/isolation & purification , Peptide Fragments/chemistry , Peptide Fragments/isolation & purification , Rats , Rats, Sprague-Dawley , Salmonella typhimurium/drug effects , Salmonella typhimurium/genetics , Toxicity Tests, Acute , Toxicity Tests, Chronic
11.
Regul Toxicol Pharmacol ; 55(3): 281-90, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19651182

ABSTRACT

Highly-branched cyclic dextrin (HBCD), a dextrin food ingredient presently only used in Japan, was investigated for digestibility and potential toxicity. HBCD was readily hydrolyzed in vitro to maltose and maltotriose by human salivary and porcine pancreatic alpha-amylases. Incubation of HBCD with a rat intestinal homogenate, containing digestive enzymes, resulted in the formation of maltose, maltotriose, and maltotetraose, and with longer incubation times, resulted in the formation of glucose. In an acute toxicity study, Wistar rats orally administered a single-dose of 2000mg/kg body weight of HBCD did not display mortality or any signs or symptoms of toxicity or abnormalities upon necropsy. Transient loose stools were observed, but were resolved within 24h of HBCD administration, and therefore, were not considered as compound-specific adverse effects. In the Ames assay, HBCD was non-mutagenic with or without metabolic activation. Toxicity testing of the branching enzyme (BE) involved in the synthesis of HBCD showed that the BE also was not acutely toxic when orally administered to rats and was non-mutagenic in the mouse lymphoma assay. The results of this study demonstrate that HBCD is digested to normal and safe products of carbohydrate digestion, and therefore, support the safety of HBCD for human consumption.


Subject(s)
1,4-alpha-Glucan Branching Enzyme/toxicity , Dextrins/toxicity , Digestion , Geobacillus stearothermophilus/enzymology , Administration, Oral , Animals , Cell Line, Tumor , Dextrins/chemistry , Dextrins/metabolism , Female , Food Additives/toxicity , Humans , Japan , Lymphoma , Male , Mice , Mutagenicity Tests , Pancreas/enzymology , Rats , Rats, Wistar , Saliva/metabolism , Swine , Toxicity Tests, Acute , alpha-Amylases/metabolism
12.
Thyroid Res ; 2(1): 5, 2009 Apr 08.
Article in English | MEDLINE | ID: mdl-19351422

ABSTRACT

BACKGROUND: Immunohistochemical methods based on the high affinity of avidin and biotin (e.g. ABC, LSAB) are characterized by high sensitivity and are widely used for detection of immunologic reaction. However, a non-specific reaction, observed in frozen tissues and in paraffin-embedded material, increasing after heat induced epitope retrieval (HIER), and caused either by endogenous biotin or any another chemical compound with high affinity for avidin, may lead to diagnostic mistakes. The aim of our investigation is to study presence of endogenous avidin biotin activity (EABA) in thyrocytes originating from various thyroid pathological lesions (neoplastic and non-neoplastic). MATERIALS AND METHODS: The immunohistochemical study was performed on paraffin-embedded specimens of surgically resected thyroid tissue from 97 patients with thyroid diseases: 65 patients with papillary carcinoma (PTC), 11 patients with nodular goiter in whom features of benign papillary hyperplasia were found, 9 with lymphocytic thyroiditis (LT), 8 with follicular adenoma, and 4 patients with follicular carcinoma. In PTC immunohistochemical study was performed both in primary tumors and in lymph node metastases. After HIER, incubation with streptavidin from LSAB+ (DakoCytomation) kit was done. RESULTS: Strong cytoplasmic EABA was observed in 56 of 65 (87.5%) PTC and in oxyphilic cells in 8 of 9 cases of LT. Significant correlation between EABA in primary PTC tumor and EABA in lymph node metastases was stated. Normal surrounding thyroid tissues showed absence or weak EABA. Aberrant intranuclear localization of biotin was noted in morules of cribriform-morular variant of PTC. No statistically significant correlation between patient's age, sex, metastases presence and EABA was observed. CONCLUSION: Among thyroid lesions, false positive reactions are highly probable in papillary thyroid carcinoma and in lymphocytic thyroiditis if immunohistochemical detection is used on systems containing (strept)avidin. The most probable reason is the high endogenous biotin content.

13.
Otolaryngol Pol ; 62(2): 175-81, 2008.
Article in Polish | MEDLINE | ID: mdl-18637442

ABSTRACT

INTRODUCTION: Head and neck cancer treatment optimization and individualization has become possible due to the implementation of the prognostic and predictive molecular markers in diagnostics. AIM: The aim of this study was an attempt to determine which of the investigated molecular markers may have prognostic and predictive value in head and neck cancers. MATERIALS AND METHODS: The paraffin blocks from 47 patients with oral and lip squamous cell carcinoma (SCC) after surgical treatment in the Institute of Oncology in Gliwice in the period of 1998-2002 were investigated. For immunohistochemical studies the DAKO monoclonal antibodies were used: p53, Ki67, Cyclin D1, Cathepsin B and Cox2-Cayman Chemical antibody. Staining reactions were evaluated at 400x magnification. The average percent of staining cells was estimated in every case in the groups of patients with (N+) and without (No) node metastases. The results were subsequently juxtaposed with selected clinical and histological parameters. Statistical analysis was performed with Mann-Whitney and Kruskal-Wallis tests and the log rank test with a significance level of 0.05 (p = 0,05). RESULTS: Significantly higher expression of Ki67 in N+ patients (p = 0,010) were recorded, although average staining in the group of treated and the group of unhealed patients was statistically insignificant. Cathepsin B expression (<20% and > 20%) was correlated with 3 year-long survival and a slight higher average staining (33,5%) in unhealed in comparison with treated patients (29,0%) was notified. Everage expression of p53 in unhealed patients (33,1%) was slightly higher than in treated ones (28,4%). Weaker Cyclin D1 expression (<10%) correlated with higher disease free survival. Average Cycline D1 staining in the groups of unhealed patients (19,6%) was higher than in the treated ones (12,0%). There were no significant differences in COX-2 staining in correlation with clinical and histological parameters. CONCLUSIONS: Lower expression of Cyclin D1 and Cathepsin B in neoplastic cells correlated with higher percentage of disease free survival what suggests the prognostic value of these markers. Higher proliferation activity of primary tumor neoplastic cells correlated with node metastases what may has the predictive value in the course of the disease.The different markers expressions observed in the different oral cavity localizations confirm the necessity to select patients for further investigations with respect to uniform disease changes topography.


Subject(s)
Biomarkers, Tumor/analysis , Carcinoma, Squamous Cell/chemistry , Mouth Neoplasms/chemistry , Mouth Neoplasms/pathology , Adult , Aged , Aged, 80 and over , Cathepsin B/analysis , Cyclin D1/analysis , Disease-Free Survival , Female , Humans , Immunohistochemistry , Ki-67 Antigen/analysis , Lip Neoplasms/chemistry , Lip Neoplasms/pathology , Male , Middle Aged , Neoplasm Staging , Poland , Predictive Value of Tests , Prognosis , Tumor Suppressor Protein p53/analysis
14.
Endokrynol Pol ; 57(4): 326-35, 2006.
Article in Polish | MEDLINE | ID: mdl-17006832

ABSTRACT

INTRODUCTION: The aim of the study was to determine the expression of selected adhesive molecules in papillary thyroid carcinoma. MATERIAL AND METHODS: 47 papillary thyroid carcinoma cases and 11 nonmalignant goiter cases were analyzed by immunohistochemistry. RESULTS: Galectin-3 (LGAL3) was a sensitive and specific marker, present in 91% of analyzed tumors and only in 5% of tumor margin. The presence of CA50 was 86% and 3% respectively with only 3% positive non-malignant cases. Cadherin E expression was noted in 91% of primary tumors, in 84% of the surrounding tissue and in 63% of non-malignant goiter. CD44 (DF1485) was observed in 89% of primary tumors and 48% of surrounding tissue; the reaction with BBA10 was more characteristic for metastases. CONCLUSIONS: Our study confirms the high diagnostic value of galectin-3 in papillary thyroid carcinoma and reveals the similar efficiency of CA50. CD44 (DF1485) expression in primary tumor is more intensive than in surrounding tissue, but the diagnostical inportance is not high because it is often observed in benign lesions. Using of BBA10 is more sensitive, but less specific. High expression of cadherin E in benign lesions impairs its diagnostical application in papillary thyroid cancer.


Subject(s)
Biomarkers, Tumor/analysis , Carcinoma, Papillary/metabolism , Carcinoma, Papillary/pathology , Thyroid Neoplasms/metabolism , Thyroid Neoplasms/pathology , Antigens, Tumor-Associated, Carbohydrate/analysis , Cadherins/analysis , Carcinoma, Papillary/chemistry , Carcinoma, Papillary/surgery , Diagnosis, Differential , Galectin 3/analysis , Goiter/metabolism , Goiter/pathology , Goiter/surgery , Humans , Hyaluronan Receptors/analysis , Immunohistochemistry , Retrospective Studies , Thyroid Neoplasms/chemistry , Thyroid Neoplasms/surgery
15.
Food Chem Toxicol ; 44(11): 1849-67, 2006 Nov.
Article in English | MEDLINE | ID: mdl-16905233

ABSTRACT

Realistic estimates of intake are essential for risk assessments of flavouring agents, since substantial over or underestimations introduce inaccuracies into such evaluations. The objectives of this study were to examine the relationship between intakes estimated using methods based on the reported volume of production [e.g., maximized survey-derived daily intake (MSDI)] versus use-level data [e.g., possible average daily intake (PADI) and modified theoretical added maximum daily intake (mTAMDI)]. The impact of volatility, self-limiting organoleptic properties and whether 10% of the population are eaters, an assumption in the MSDI calculation, on intake estimates were investigated. Analyses on 221 flavouring substances showed that intake estimates derived from MSDI correlated with values determined from detailed 14-day menu-census data, PADI, and mTAMDI. Comparisons of menu-census intake data adjusted to account for factors such as volatile losses showed that MSDI estimates are realistic and sufficiently conservative, whereas mTAMDI results in substantial overestimates of intake. Very few flavours have less than 10% eaters, and in the worst case, this assumption underestimates percent eaters by a factor of about 4. This investigation supports the use of MSDI as a conservative yet practical method to estimate intake of flavouring substances.


Subject(s)
Consumer Product Safety , Diet Surveys , Diet , Flavoring Agents/administration & dosage , Eating , Flavoring Agents/analysis , Food Analysis/methods , Humans , Reproducibility of Results , Risk Assessment
16.
Endokrynol Pol ; 56(5): 752-7, 2005.
Article in Polish | MEDLINE | ID: mdl-16817140

ABSTRACT

In our study we present chosen elements of microarray analysis of gene expression profile in papillary thyroid cancer. The study group included 16 papillary thyroid cancer tissues and 16 corresponding normal tissues. Samples were analyzed on high density oligonucleotide microarrays (GeneChip HG-U133A) which contain 22.000 genes. 110 genes, which had significant changed expression, were selected by MAS 5.0 program. 3 genes were chosen to the deeper analysis: dipeptidylpeptidase 4 (DPP4), fibronectin 1 (FN1), tissue inhibitor of metalloproteinase 1 (TIMP1). DPP4-RNA were absent in normal tissue while in cancer tissue it was detected in large amount. FN1 and TIMP1 expression were detected in normal tissue but markedly increased in papillary thyroid cancer. Among these 3 genes DPP4 seems to be the best molecular marker for papillary thyroid cancer.


Subject(s)
Carcinoma, Papillary/genetics , Gene Expression Profiling/methods , Oligonucleotide Array Sequence Analysis , Thyroid Neoplasms/genetics , Adenosine Deaminase/metabolism , Carcinoma, Papillary/metabolism , Dipeptidyl Peptidase 4/metabolism , Gene Expression Regulation, Neoplastic , Glycoproteins/metabolism , Humans , Intercellular Signaling Peptides and Proteins , Peptides/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Thyroid Neoplasms/metabolism , Tissue Inhibitor of Metalloproteinase-1/metabolism
17.
Birth Defects Res A Clin Mol Teratol ; 70(8): 528-30, 2004 Aug.
Article in English | MEDLINE | ID: mdl-15329830

ABSTRACT

BACKGROUND: Case-control studies have suggested that the nausea and vomiting of pregnancy (NVP) may have a protective effect against specific malformations. These suggestions have been interpreted as if the lack of NVP may put mothers at an increased teratogenic risk. METHODS: A prospective, cohort-controlled study was done comparing pregnancy outcome in women not experiencing NVP with those experiencing NVP at two levels of clinical severity. Women who called the Motherisk program about first-trimester exposure to drugs and who had not experienced NVP were included as the study group. The NVP Healthline enrolled two control groups of women with NVP treated with a doxylamine-pyridoxine combination for morning sickness. These women were exposed during the first trimester of gestation to either higher than the standard dose (5-12 tablets/day) or a standard dose (1-4 tablets/day) of doxylamine-pyridoxine. The women in all three groups were followed up four to six months after the expected date of birth to ascertain pregnancy outcomes and child health. RESULTS: There were no major malformations among offspring of 130 women not experiencing NVP. There were two major malformations among 246 women experiencing NVP. The two control groups of women with NVP had similar distributions of gestational ages, birth rates, as well as rates of miscarriages and stillbirths, as in the no-NVP group. CONCLUSIONS: This study did not show an association between lack of NVP and an increase in the overall rates of major malformations.


Subject(s)
Congenital Abnormalities/epidemiology , Morning Sickness/epidemiology , Adult , Antiemetics/therapeutic use , Congenital Abnormalities/prevention & control , Doxylamine/therapeutic use , Female , Genetic Counseling , Humans , Maternal Age , Pregnancy , Pregnancy Outcome , Pyridoxine/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...